Click here to read this study in JAMA. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced...
Click here to read this study in The Lancet. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be...
1. Clinically relevant bleeding was significantly lower with ticagrelor monotherapy than in the ticagrelor plus aspirin group. 2. Major cardiovascular...
Click here to read this study in the Journal of Clinical Oncology ©2024 2 Minute Medicine, Inc. All rights reserved. No...
Click here to read the study in JAMA. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced...
1. Progression-free survival at 24 months was higher in the pembrolizumab versus placebo-controlled group. 2. The pembrolizumab-chemoradiotherapy group reported slightly...
1. The overall survival at 48 months was 91.2% in the pembrolizumab group vs 86.0% in the placebo group, with...
1. Overall vaccine efficacy ranged from 83.1% to 86.6% during the 10-year period. 2. Detectable concentrations of antibodies persisted at...
Click here to read this study in JMIG. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be...
1. Significantly more patients in the imetelstat group achieved RBC transfusion independence at 8 weeks after treatment compared to placebo....
